Eric J Topol & Akiko Iwasaki –
Just 10 months after the initial genome sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, two mRNA vaccines were demonstrated to provide 95% efficacy against symptomatic infections via randomized, placebo-controlled trials of more than 74,000 participants (1). That unprecedented success was, in part, fueled by the $10 billion governmental investment in Operation Warp Speed (OWS) in March 2020 to accelerate the development, manufacturing, and distribution of coronavirus disease 2019 (COVID-19) vaccines. We urgently need such an accelerated initiative now for nasal vaccines.
Read the full editorial in Science Immunology.
